Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CD4 | P01730 | 9/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14152085 | 0.93 | NPC1 (0.39) | NPC1RAB9ACD4KDM4EALDH1A1 | |
| SCHEMBL14150568 | 0.91 | ALDH1A1 (0.43) | NPC1RAB9ACD4KDM4EALDH1A1 | |
| SCHEMBL6910948 | 0.87 | DRD4 (0.44) | KDM4EALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL6911454 | 0.85 | GAA (0.38) | KDM4EALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL2358302 | 0.84 | DRD4 (0.43) | KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL2355545 | 0.82 | ALDH1A1 (0.52) | CD4KDM4EALDH1A1SMN1; SMN2GAA | |
| SCHEMBL2346588 | 0.80 | CD4 (0.51) | CD4ALDH1A1SMN1; SMN2TSHRGAA | |
| SCHEMBL2358075 | 0.77 | CD4 (0.41) | CD4SMN1; SMN2KMT2A | |
| SCHEMBL2358544 | 0.76 | TP53 (0.41) | CD4ALDH1A1KMT2AHTTGAA | |
| SCHEMBL2355656 | 0.76 | CYP3A4 (0.46) | CD4KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748456-B2 | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2014-06-10 | — | — | US | claimed |
| US-20120316380-A1 | Pyrazolo Piperidine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX SA (CH) | 2012-12-13 | — | — | US | claimed |
| US-8748456-B2 | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2014-06-10 | — | — | US | disclosed |
| US-8748456-B2 | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2014-06-10 | — | — | US | disclosed |
| US-8748456-B2 | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2014-06-10 | — | — | US | disclosed |
| EP-2536721-A1 | PYRAZOLO PIPERIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GenKyoTex SA (CH) | 2012-12-26 | — | — | EP | disclosed |
| US-20120316380-A1 | Pyrazolo Piperidine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX SA (CH) | 2012-12-13 | — | — | US | disclosed |
| US-20120316380-A1 | Pyrazolo Piperidine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX SA (CH) | 2012-12-13 | — | — | US | disclosed |
| US-20120316380-A1 | Pyrazolo Piperidine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX SA (CH) | 2012-12-13 | — | — | US | disclosed |
| WO-2011101805-A1 | PYRAZOLO PIPERIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011101805-A1 | PYRAZOLO PIPERIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316380-A1 | Pyrazolo Piperidine Derivatives as NADPH Oxidase Inhibitors | NOX1, NOX4, NOX5 | NPC1 1531/4885RAB9A 2296/4885CD4 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.